Feasibility of cell transplantation with a left ventricular assist device to improve the success rate of left ventricular assist device removal: The first experiment

Interactive Cardiovascular and Thoracic Surgery

Volumn 12, Issue 1, 2011, Pages 11-14

  Mizuno, Tomohiro ^a  

^a Machida Municipal Hospital   (Japan)

Author keywords

Cardiac function; Cell transplantation; Heart failure; Left ventricular assist device

Indexed keywords

GELATINASE A; GELATINASE B; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 3; MMP2 PROTEIN, RAT; TISSUE INHIBITOR OF METALLOPROTEINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL TRANSPLANTATION; CONTROLLED STUDY; DEVICE REMOVAL; HEART ASSIST DEVICE; HEART DILATATION; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE PRESSURE; HEART LEFT VENTRICLE VOLUME; HEART LUNG TRANSPLANTATION; HEART STIMULATION; HISTOLOGY; INTERMETHOD COMPARISON; MALE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RAT; RECURRENT DISEASE; SMOOTH MUSCLE FIBER; ANIMAL; CELL CULTURE; FEASIBILITY STUDY; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART VENTRICLE; HEART VENTRICLE PRESSURE; HETEROTOPIC TRANSPLANTATION; LEWIS RAT; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; REOPERATION; TIME; TRANSPLANTATION;

ANIMALS; CELLS, CULTURED; DEVICE REMOVAL; FEASIBILITY STUDIES; HEART VENTRICLES; HEART-ASSIST DEVICES; HEART-LUNG TRANSPLANTATION; HYPERTROPHY, LEFT VENTRICULAR; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MYOCYTES, SMOOTH MUSCLE; RATS; RATS, INBRED LEW; REOPERATION; TIME FACTORS; TISSUE INHIBITOR OF METALLOPROTEINASES; TRANSPLANTATION, HETEROTOPIC; VENTRICULAR FUNCTION, LEFT; VENTRICULAR PRESSURE;

EID: 78650871071     PISSN: 15699293     EISSN: 15699285     Source Type: Journal    
DOI: 10.15.1510/icvts.2010.239806     Document Type: Article

References (15)

1. DeRose JJ Jr, Umana JP, Argenziano M, Catanese KA, Gardocki MT, Flannery M, Levin HR, Sun BC, Rose EA, Oz MC. Implantable left ventricular assist devices provide an excellent outpatient bridge to transplantation and recovery. J Am Coll Cardiol 1997;30:1773-1777.
2. Kumpati GS, McCarthy PM, Hoercher KJ. Left ventricular assist deviceas a bridge to recovery: present status. J Card Surg 2001;16:294-301.
3. Entwistle JW. Long-term mechanical ventricular assistance toward myocardial recovery. Cardiol Clin 2003:21:75-82.
4. Hetzer R, Muller JH, Weng YG, Loebe M, Wallukat G. Midterm followup of patients who underwent removal of a left ventricular assist device after cardiac recovery from end-stage dilated cardiomyopathy. J Thorac Cardiovasc Surg 2000;120:843-855.
5. Mancini DM, Beniaminovitz A, Levin H, Catanese K, Flannery M, DiTullio M, Savin S, Cordisco ME, Rose E, Oz M. Low incidence of myocardial recovery after left ventricular assist device implantation in patients with chronic heart failure. Circulation 1998;98:2383-2389.
6. Ghostine S, Carrion C, Souza LCG, Richard P, Bruneval P, Vilquin JT, Pouzet B, Schwartz K, Menasché P, Hagège AA. Long-term efficacy of myoblast transplantation on regional structure and function after myocardial infarction. Circulation 2002;106:I131-I136.
7. Tomita S, Li RK, Weisel RD, Mickle DAG, Kim EJ, Sakai T, Jia ZQ. Autologous transplantation of bone marrow cells improves damaged heart function. Circulation 1999;100:II247-II256.
8. Mizuno T, Weisel RD, Li RK. Reloading the heart: a new animal model of left ventricular assist device removal. J Thorac Cardiovasc Surg 2005;130:99-106.
9. Li RK, Jia ZQ, Weisel RD, Merante F, Mickle DA. Smooth muscle cell transplantation into myocardial scar tissue improves heart function. J Mol Cell Cardiol 1999;31:513-522.
10. Fedak PWM, Szmitko PE, Weisel RD, Altamentova SM, Nili N, Ohno N, Verma S, Fazel S, Strauss BH, Li RK. Cell transplantation preserves matrix homeostasis: a novel paracrine mechanism. J Thorac Cardiovasc Surg 2005;130:1430-1439.
11. Fedak PWM, Altamentova SM, Weisel RD, Nili N, Ohno N, Verma S, Lee TYJ, Kiani C, Mickle DAG, Strauss BH, Li RK. Matrix remodeling in experimental and human heart failure: a possible regulatory role for TIMP-3. Am J Physiol Heart Circ Physiol 2003;284:H626-H634.
12. Menasché P, Alfieri O, Janssens S, McKenna W, Reichenspurner H, Trinquart L, Vilquin JT, Marolleau JP, Seymour B, Larghero J, Lake S, Chatellier G, Solomon S, Desnos M, Hagège AA. The myoblast autologous grafting in ischemic cardiomyopathy (MAGIC) trial: first randomized placebo-controlled study of myoblast transplantation. Circulation 2008;117:1189-1200.
13. Mizuno T, Yau TM, Weisel RD, Kiani CG, Li RK. Elastin stabilizes an infarct and preserves ventricular function. Circulation 2005;112:I81-I88.
14. Li YY, Feng Y, McTiernan CF, Pei W, Moravec CS, Wang P, Rosenblum W, Kormos RL, Feldman AM. Downregulation of matrix metalloproteinases and reduction in collagen damage in the failing human heart after support with left ventricular assist devices. Circulation 2001;104:1147-1152.
15. Torre-Amione G, Stetson SJ, Youker KA, Durand JB, Radovancevic B, Delgado RM, Frazier OH, Entman ME, Noon P. Decreased expression of tumor necrosis factor-a in failing human myocardium after mechanical circulatory support. A potential mechanism for cardiac recovery. Circulation 1999;100:1189-1193.